Biologics

Researchers at New York City-based Hospital for Special Surgery and Weill Cornell Medicine discovered a new stem cell that could affect spine care.

Creative Medical Technology Holdings got FDA clearance for its Phase 1/2 clinical trial for its StemSpine procedure using AlloStem, according to a Sept. 19 news release.

Here are five updates on orthopedic regenerative medicine Becker's has reported on since Aug. 15: 

In the last 12 months, two orthobiologics companies have expanded their focus and rebranded.

HippoFi and Zimmer Biomet are partnering to develop and launch a novel synthetic biomaterial for bone growth.

A group of lawmakers wrote a letter to Robert Califf, MD, the U.S. FDA commissioner, pushing for stricter guidance for bone grafts in light of a recent spate of tuberculosis linked to orthopedic products.

The consensus on whether regenerative medicine is effective in sports medicine is still up in the air, according to Michael Ciccotti, MD, of Rothman Orthopaedic Institute in Philadelphia.

A Michigan woman died from tuberculosis linked to tainted bone graft, The Detroit News reported Aug, 18.

Aziyo Biologics is in talks to divest its orthopedic business, the company said Aug. 14.

Here are five developments in orthopedic regenerative medicine since July 11.